Fulvestrant Injection
Product Images NDC 16729-436

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 16729-436). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Fulvestrant (Fulvestrant Injection Carton)

Fulvestrant (Fulvestrant Injection Carton)
This text seems to be a combination of medical instructions and product information for Fulvestrant injection, a medication used for treating breast cancer. It includes advice on proper handling, storing, administration procedures, and dosages. It also highlights the presence of two SafetyGlide™ shielding intramuscular injection needles and mentions the need for their proper discard after use.*
FDA Label Image

Chemical Structure Fulvestrant (Fulvestrant Injection Chemical Structure)

Chemical Structure Fulvestrant (Fulvestrant Injection Chemical Structure)
FDA Label Image

Figure 1 (Fulvestrant Injection Figure 1)

Figure 1 (Fulvestrant Injection Figure 1)
FDA Label Image

Figure_10 (Fulvestrant Injection Figure 10)

Figure_10 (Fulvestrant Injection Figure 10)
FDA Label Image

Figure 11 (Fulvestrant Injection Figure 11)

Figure 11 (Fulvestrant Injection Figure 11)
FDA Label Image

Figure 12 (Fulvestrant Injection Figure 12)

Figure 12 (Fulvestrant Injection Figure 12)
This appears to be a graph showing the results of a study comparing the effectiveness of two drugs, Fulvestrant plus Abemaciclib and Fulvestrant plus Placebo, on Palionks at ok Time (months). There were 446 participants in the Fulvestrant plus Abemaciclib group and 223 in the Fulvestrant plus Placebo group. The graph shows that the Fulvestrant plus Abemaciclib group had higher Palionks scores compared to the Fulvestrant plus Placebo group. There were 100 censored observations, and the time range was from 0 to 57 months.*
FDA Label Image

Figure 13 (Fulvestrant Injection Figure 13)

Figure 13 (Fulvestrant Injection Figure 13)
FDA Label Image

Figure 14 (Fulvestrant Injection Figure 14)

Figure 14 (Fulvestrant Injection Figure 14)
FDA Label Image

Figure 2 (Fulvestrant Injection Figure 2)

Figure 2 (Fulvestrant Injection Figure 2)
FDA Label Image

Figure 3 (Fulvestrant Injection Figure 3)

Figure 3 (Fulvestrant Injection Figure 3)
FDA Label Image

Figure 4 (Fulvestrant Injection Figure 4)

Figure 4 (Fulvestrant Injection Figure 4)
FDA Label Image

Figure 5 (Fulvestrant Injection Figure 5)

Figure 5 (Fulvestrant Injection Figure 5)
FDA Label Image

Fig 6 Kaplan-maier Pfs: Study 1 Itt Population (Fulvestrant Injection Figure 6)

Fig 6 Kaplan-maier Pfs: Study 1 Itt Population (Fulvestrant Injection Figure 6)
This appears to be a table displaying results from a study or clinical trial involving two different dosages of the drug Fulvestrant (250mg and 500mg). The numbers listed under "Number at risk" likely show how many participants were still being monitored at different time intervals (measured in months) throughout the study. The numbers in the subsequent columns likely show how many of those participants experienced some outcome or event of interest. Without additional context or information about what the study was measuring, it is difficult to provide a more detailed description.*
FDA Label Image

Figure 7 Kaplan-meier Os (minimum Follow-up Duration Of 50 Months): Confirm Itt Population (Fulvestrant Injection Figure 7)

Figure 7 Kaplan-meier Os (minimum Follow-up Duration Of 50 Months): Confirm Itt Population (Fulvestrant Injection Figure 7)
This is a graph showing the proportion of patients alive over time. Two treatments are compared: Fulvestrant 500mg and Fulvestrant 250mg. The X-axis shows the time in months, and the Y-axis shows the percentage of patients alive. The graph suggests that patients treated with Fulvestrant 500mg had a higher proportion of survival compared to those treated with 250mg, but the difference is not statistically significant. The graph also indicates that some patients’ observations were censored.*
FDA Label Image

Figure_8.jpg (Fulvestrant Injection Figure 8)

Figure_8.jpg (Fulvestrant Injection Figure 8)
FDA Label Image

Figure_9 (Fulvestrant Injection Figure 9)

Figure_9 (Fulvestrant Injection Figure 9)
FDA Label Image

Fulvestrant (Fulvestrant Injection Label)

Fulvestrant (Fulvestrant Injection Label)
This is a product description of a fulvestrant injection with a concentration of 50mg/mL, administered intramuscularly with a 500mg dose requiring two pre-filled syringes. The manufacturer is Intas Pharmaceuticals Limited and the product is distributed by IN5125. The NDC code is 16729-436-31.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.